Article Text
Abstract
Chagas’ disease reactivation leading to monophasic acute or subacute meningoencephalitis or space-occupying lesions is a well-described AIDS-defining condition in Latin America. We report a 59-year-old man native from the Northeast region of Brazil, with a second episode of subacute chagasic meningomyelitis. He had long-term multidrug-resistant HIV and had abandoned combined antiretroviral therapy (CD4+ lymphocyte count, 16 cells/mm³, and HIV viral load 169 403 copies/mL). He initially received benznidazole but switched to nifurtimox after developing myelotoxicity. He was discharged home having made a partial neurological improvement. Chagas’ disease should be included in the differential diagnosis of meningomyelitis in people living with HIV/AIDS who are from endemic areas of this parasitic disease.
- INFECTIOUS DISEASES
- TROPICAL NEUROLOGY
- CLINICAL NEUROLOGY
- AIDS
- MYELOPATHY
Data availability statement
Data sharing not applicable as no datasets generated and/or analysed for this study.
Statistics from Altmetric.com
Data availability statement
Data sharing not applicable as no datasets generated and/or analysed for this study.
Footnotes
Contributors 1 - Article project: A. Conception, B. Organisation, C. Execution, D. Supervision. 2 - Manuscript: A. Writing of the first draft; B. Review and Critique. IMdA: 1A, 1B, 1C, 2A, 2B (Nothing to disclose). ABMdR: 1A, 1B, 1C, 2A, 2B (Nothing to disclose). ACPO: 1A, 2B (Nothing to disclose). JALL: 1A, 2B (Nothing to disclose). VLTdF: 1A, 2B (Nothing to disclose). JEV: 1A, 2B, 1D (Nothing to disclose).
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Map disclaimer The depiction of boundaries on this map does not imply the expression of any opinion whatsoever on the part of BMJ (or any member of its group) concerning the legal status of any country, territory, jurisdiction or area or of its authorities. This map is provided without any warranty of any kind, either express or implied.
Competing interests None declared.
Provenance and peer review Not commissioned. Externally peer reviewed by Jonathan Underwood, Cardiff, UK.
Read the full text or download the PDF:
Other content recommended for you
- New chemotherapy regimens and biomarkers for Chagas disease: the rationale and design of the TESEO study, an open-label, randomised, prospective, phase-2 clinical trial in the Plurinational State of Bolivia
- Neglected tropical cardiomyopathies: I. Chagas disease
- Limited infant exposure to benznidazole through breast milk during maternal treatment for Chagas disease
- Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas’ disease
- Cross-sectional, descriptive study of Chagas disease among citizens of Bolivian origin living in Munich, Germany
- Is use of nifurtimox for the treatment of Chagas disease compatible with breast feeding? A population pharmacokinetics analysis
- Eliminating Chagas disease: challenges and a roadmap
- Severe immune thrombocytopaenia in a patient taking benznidazole for chronic Chagas disease
- Longitudinal study of patients with chronic Chagas cardiomyopathy in Brazil (SaMi-Trop project): a cohort profile
- Combined use of two rapid tests for the conclusive diagnosis of Chagas disease: a systematic scoping review